Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PIFR-2)

  • STATUS
    Recruiting
  • End date
    Sep 10, 2022
  • participants needed
    366
  • sponsor
    Theravance Biopharma
Updated on 10 May 2022

Summary

Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.

Details
Condition Chronic Obstructive Pulmonary Disease
Treatment Tiotropium, Revefenacin, Revefenacin Placebo, Tiotropium Placebo
Clinical Study IdentifierNCT05165485
SponsorTheravance Biopharma
Last Modified on10 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Participant is a male or female 40 years of age or older
Participant is female and is nonpregnant and nonlactating. A woman of childbearing potential must have a documented negative urine pregnancy test at screening. Women are considered not to be of childbearing potential if they have had a total hysterectomy and/or bilateral tubal ligation (documentation for either must be provided before enrollment) or are at least 2 years postmenopausal
During the study and for 30 days after receiving the last dose of study drug, women of childbearing potential and men capable of fathering children must agree to use highly effective birth control measures or agree to abstain from sexual intercourse
A highly effective method of birth control is defined as one that results in a
low failure rate (i.e. <1% per year) when used consistently and correctly
such as condom \+ diaphragm, condom + spermicide, diaphragm + spermicide, or
intrauterine device [IUD] with documented failure rate of <1% per year, or
oral/injectable/implanted hormonal contraceptives used in combination with an
additional barrier method
Participant has a diagnosis of COPD, specifically, a post-ipratropium FEV1/FVC ratio <0.7
Participant has a postipratropium FEV1 < 50% of predicted normal (using National Health and Nutrition Examination Survey-predicted equations) and absolute FEV1 > 700 mL
Participant has a PIFR <60 L/min as measured by an In-Check™ device with resistance set to DISKUS at Visit 1A (if not combined with Visit 1B) and < 55 L/min as measured by an In-Check™ device with resistance set to DISKUS at Visit 1B and Visit 2 prior to randomization
Participant is capable of performing reproducible spirometry maneuvers (and plethysmography maneuvers for a subset of participants) as described by current American Thoracic Society (ATS) Guidelines
Participant is an active or former smoker with a cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack-years
Participant or legal guardian is willing and able to provide signed and dated informed consent to participate prior to initiation of any study related procedures
Participant is willing and able to adhere to all study assessments/procedures. Care partner assistance is acceptable
Participant is willing and able to adhere to all restrictions during their study participation as follows
Use of recreational drugs
Medicinal marijuana
Excessive alcohol during the study period
Participation in another investigational drug study
Donation of ≥500 mL blood (or equivalent)
Participant (or care partner) based on the investigator's assessment is able to
properly prepare and administer study medication administered from both
nebulizer and HandiHaler® according to their respective Instructions for Use

Exclusion Criteria

Participant has a concurrent disease or condition that, in the opinion of the investigator, would interfere with study participation or confound the evaluation of safety and tolerability of the study drug
Participant has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics
Participant suffers from any medical condition that would preclude the use of inhaled anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention
Participant has Moderate to Severe Hepatic impairment (Child-Pugh B or C) or Severe Renal Insufficiency (i.e. a glomerular filtration rate <30 mL/min/1.72m2)
Participant has been hospitalized for COPD or pneumonia within 8 weeks prior to Visit 1\
Participant is receiving a LABA or LABA/inhaled corticosteroid (ICS; either QD or BID) at a dose that has been stable for ≤ 30 days prior to screening
Participant has used systemic corticosteroids within 8 weeks of Visit 1
Participant has used antibiotics for respiratory tract infections within 8 weeks of Visit 1, or is using antibiotics prophylactically
Participant received COVID-19 vaccine within 2 weeks prior to Visit 1
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note